• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    9/19/23 5:31:40 PM ET
    $AVGR
    $BJDX
    $CDIO
    $CFRX
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AVGR alert in real time by email

    Gainers

    • Fresh Tracks Therapeutics (NASDAQ:FRTX) stock increased by 49.1% to $0.86 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 2.6 million shares, which is 428.9 percent of its average volume over the last 100 days. The company's market cap stands at $5.1 million.
    • Histogen (NASDAQ:HSTO) stock increased by 37.94% to $0.54. At the close, Histogen's trading volume reached 455.7K shares. This is 839.3% of its average volume over the last 100 days. The market value of their outstanding shares is at $2.3 million.
    • Avinger (NASDAQ:AVGR) stock rose 37.32% to $14.35. Avinger's trading volume hit 7.3 million shares by close, accounting for 1113.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $10.2 million.
    • Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) stock increased by 19.99% to $0.0. Longeveron Inc. - Subscription Right's trading volume hit 206.5K shares by close, accounting for 27.1% of its average volume over the last 100 days.
    • Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 14.51% to $3.55. The company's market cap stands at $4.3 million.
    • Exagen (NASDAQ:XGN) shares increased by 14.14% to $2.69. The market value of their outstanding shares is at $45.4 million.

    Losers

    • Novo Integrated Sciences (NASDAQ:NVOS) shares declined by 12.0% to $0.22 during Tuesday's after-market session. Trading volume for this security closed at 5.9 million, accounting for 13.8% of its average full-day volume over the last 100 days. The company's market cap stands at $34.6 million.
    • ContraFect (NASDAQ:CFRX) stock decreased by 7.43% to $0.54. The market value of their outstanding shares is at $5.8 million.
    • HilleVax (NASDAQ:HLVX) shares fell 6.94% to $13.43. The company's market cap stands at $526.6 million.
    • IN8bio (NASDAQ:INAB) shares declined by 6.8% to $0.96. The market value of their outstanding shares is at $30.3 million.
    • Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock fell 6.41% to $0.4. The market value of their outstanding shares is at $4.7 million.
    • OKYO Pharma (NASDAQ:OKYO) shares decreased by 6.19% to $1.82. The company's market cap stands at $51.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AVGR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVGR
    $BJDX
    $CDIO
    $CFRX

    CompanyDatePrice TargetRatingAnalyst
    OKYO Pharma Limited
    $OKYO
    2/20/2026$7.00Overweight
    Piper Sandler
    OKYO Pharma Limited
    $OKYO
    12/8/2025$5.00Buy
    B. Riley Securities
    Exagen Inc.
    $XGN
    9/11/2025$15.00Buy
    B. Riley Securities
    Exagen Inc.
    $XGN
    7/30/2025$12.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Exagen Inc.
    $XGN
    7/23/2025$12.00Buy
    Craig Hallum
    HilleVax Inc.
    $HLVX
    7/9/2024$28.00 → $2.00Outperform → Market Perform
    Leerink Partners
    HilleVax Inc.
    $HLVX
    7/9/2024$34.00 → $3.00Buy → Hold
    Stifel
    HilleVax Inc.
    $HLVX
    7/9/2024$28.00 → $2.00Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $AVGR
    $BJDX
    $CDIO
    $CFRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on OKYO Pharma with a new price target

    Piper Sandler initiated coverage of OKYO Pharma with a rating of Overweight and set a new price target of $7.00

    2/20/26 8:25:04 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on OKYO Pharma with a new price target

    B. Riley Securities initiated coverage of OKYO Pharma with a rating of Buy and set a new price target of $5.00

    12/8/25 8:35:27 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Exagen with a new price target

    B. Riley Securities initiated coverage of Exagen with a rating of Buy and set a new price target of $15.00

    9/11/25 8:42:21 AM ET
    $XGN
    Medical Specialities
    Health Care

    $AVGR
    $BJDX
    $CDIO
    $CFRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the "Company") (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative γδ T cell therapies for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 11,800 shares of its common stock. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted outside of the Company's 2023 Equity Incentive Plan, with a grant date of April 1, 2026, as an inducement material to the new employees entering into employment with the Company, in ac

    4/3/26 4:00:00 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Chairman and Founder Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically

    3/19/26 12:00:00 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Director Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company's ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as

    3/19/26 10:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVGR
    $BJDX
    $CDIO
    $CFRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Fung Peter K

    4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    4/2/26 2:21:52 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Betts Wendy J

    4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    4/2/26 2:18:23 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Intrater James

    4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    4/2/26 2:08:32 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AVGR
    $BJDX
    $CDIO
    $CFRX
    SEC Filings

    View All

    SEC Form DEFA14A filed by IN8bio Inc.

    DEFA14A - IN8BIO, INC. (0001740279) (Filer)

    3/26/26 4:07:49 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by IN8bio Inc.

    DEF 14A - IN8BIO, INC. (0001740279) (Filer)

    3/26/26 4:05:33 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by OKYO Pharma Limited

    6-K - OKYO Pharma Ltd (0001849296) (Filer)

    3/19/26 12:00:01 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVGR
    $BJDX
    $CDIO
    $CFRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Black Jeffrey G. bought $66,448 worth of shares (22,298 units at $2.98), increasing direct ownership by 9% to 274,492 units (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    11/19/24 7:24:38 PM ET
    $XGN
    Medical Specialities
    Health Care

    President and CEO Aballi John bought $68,297 worth of shares (24,305 units at $2.81), increasing direct ownership by 4% to 689,799 units (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    11/18/24 6:32:33 PM ET
    $XGN
    Medical Specialities
    Health Care

    Amendment: Chief Technology Officer Dogan Timur bought $20,000 worth of shares (68,965 units at $0.29) (SEC Form 4)

    4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    10/9/24 1:18:30 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AVGR
    $BJDX
    $CDIO
    $CFRX
    Leadership Updates

    Live Leadership Updates

    View All

    OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

    Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to advance the company's development program in neuropathic corneal pain (NCP), leveraging urcosimod's FDA Fast Track designationThis appointment, following the recent CEO appointment, further strengthens OKYO's world-class ophthalmology leadership team LONDON and NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neur

    2/10/26 8:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer

    Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board LONDON and NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announces that, effective immediately, Robert J. Dempsey will assume the role of Chief Executive Officer. Gary S. Jacob, Ph.D. will transition to Chief Development Officer and

    1/5/26 7:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exagen Inc. Appoints Chas McKhann to Board of Directors

    CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann served as Board member, President and CEO of Silk Road Medical, and prior to that, Apollo Endosurgery, both Nasdaq-listed companies acquired by Boston Scientific, resulting in significant shareholde

    7/17/25 4:05:00 PM ET
    $XGN
    Medical Specialities
    Health Care

    $AVGR
    $BJDX
    $CDIO
    $CFRX
    Financials

    Live finance-specific insights

    View All

    OKYO Pharma Announces Chairman and Founder Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically

    3/19/26 12:00:00 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Director Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company's ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as

    3/19/26 10:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 108,920 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammat

    3/19/26 7:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVGR
    $BJDX
    $CDIO
    $CFRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Exagen Inc.

    SC 13G/A - EXAGEN INC. (0001274737) (Subject)

    12/12/24 5:00:54 PM ET
    $XGN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bluejay Diagnostics Inc.

    SC 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 3:54:54 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care